Progress in Assays of HMGB1 Levels in Human Plasma-The
Potential Prognostic Value in COVID-19

J 2022

Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19

ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ and Petr SKLÁDAL

Basic information

Original name

Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19

Authors

ŠTROS, Michal (guarantor), Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ (203 Czech Republic, belonging to the institution) and Petr SKLÁDAL (203 Czech Republic, belonging to the institution)

Edition

Biomolecules, Basel, MDPI, 2022, 2218-273X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.500

RIV identification code

RIV/00216224:14310/22:00126405

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.3390/biom12040544

UT WoS

000787419100001

Keywords in English

HMGB1; plasma/serum; ELISA; EMSA; immunosensor; COVID-19

Abstract

V originále

Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.

Links

NU20-08-00106, research and development project

Name: Elektrochemický imunodetektor pro detekci HMGB1 v séru pacientů s různými formami leukémie: metoda pro rychlé zhodnocení úspěšnosti léčby

Investor: Ministry of Health of the CR, Subprogram 1 - standard

Citovat

ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ and Petr SKLÁDAL. Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19. Biomolecules. Basel: MDPI, 2022, vol. 12, No 4, p. 1-11. ISSN 2218-273X. Available from: https://dx.doi.org/10.3390/biom12040544.

@article{2210924,
   author = {Štros, Michal and Volfová Polanská, Eva and Hlaváčová, Tereza and Skládal, Petr},
   article_location = {Basel},
   article_number = {4},
   doi = {http://dx.doi.org/10.3390/biom12040544},
   keywords = {HMGB1; plasma/serum; ELISA; EMSA; immunosensor; COVID-19},
   language = {eng},
   issn = {2218-273X},
   journal = {Biomolecules},
   title = {Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19},
   url = {https://www.mdpi.com/2218-273X/12/4/544},
   volume = {12},
   year = {2022}
}

TY  - JOUR
ID  - 2210924
AU  - Štros, Michal - Volfová Polanská, Eva - Hlaváčová, Tereza - Skládal, Petr
PY  - 2022
TI  - Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19
JF  - Biomolecules
VL  - 12
IS  - 4
SP  - 1-11
EP  - 1-11
PB  - MDPI
SN  - 2218273X
KW  - HMGB1
KW  - plasma/serum
KW  - ELISA
KW  - EMSA
KW  - immunosensor
KW  - COVID-19
UR  - https://www.mdpi.com/2218-273X/12/4/544
N2  - Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.
ER  -

ŠTROS, Michal, Eva VOLFOVÁ POLANSKÁ, Tereza HLAVÁČOVÁ and Petr SKLÁDAL. Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19. \textit{Biomolecules}. Basel: MDPI, 2022, vol.~12, No~4, p.~1-11. ISSN~2218-273X. Available from: https://dx.doi.org/10.3390/biom12040544.

Detailed Information on Publication Record